CNBC Global CFO Council

Nicholas C. Fanandakis, DuPont

Nicholas Fanandakis
Source: DuPont
Nicholas Fanandakis

Nicholas C. Fanandakis is executive vice president and chief financial officer of DuPont. He joined the company in 1979 as an accounting and business analyst in the Petrochemicals Department in Wilmington, Del.

Over the next several years, Fanandakis served in a variety of plant, marketing, and product management positions within Petrochemicals, Chemicals and Pigments and Specialty Chemicals. He also spent about six years in the Fluorochemicals business. In 1993, he was appointed regional manager in Specialty Chemicals. In 1995, he was appointed business manager for Safety and Environmental Management Services. In January 1997, he was appointed to the position of global business and operations manager - Peroxygens.

In October 1999, Fanandakis was appointed to the position of business director - Industrials, with responsibility for the Industrial Solutions market space, which includes Acrylonitrile, Anchorage Systems, Aniline, Aramid Intermediates, Cyanides, Dimethyl Sulfate, Methylamines, Reactive Metals, Refinery, Secure Environmental Treatment and DuPont Vazo Free Radical Initiators. He was named vice president and general manager - DuPont Chemical Solutions Enterprise in September 2003. In February 2007 he was named vice president - Corporate Plans. In January 2008 he was named group vice president - DuPont Applied BioSciences. He was named to his current position in November 2009.

Fanandakis was born in Boston. He received a B.A. in accounting and an MBA from Northeastern University (1979) and Grand Valley State College (1984).


CNBC Global CFO Council


  • Jan Siegmund, ADP CFO, and Bill Gerber, TD Ameritrade CFO, discuss how America's corporate leaders are viewing today's employment data and the current state of the U.S. economy.

  • Jon Moeller, Procter & Gamble CFO, breaks down P&G's quarterly numbers and discusses the company's cost-cutting measures.

  • UPS CFO Kurt Kuehn on CNBC's Squawk on the Street on his company's decision to stop deliveries for illegal online pharmacies and pay $40 million to end a Federal criminal probe into its shipping practices. Rival FedEx was in court today fighting similar charges.